NovoCure Limited (NVCR)
NASDAQ: NVCR · IEX Real-Time Price · USD
19.02
+0.37 (1.98%)
Jul 26, 2024, 4:00 PM EDT - Market closed
NovoCure Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year Ending | TTM | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | 2018 - 2013 |
|---|---|---|---|---|---|---|---|
| Revenue | 549.96 | 509.34 | 537.84 | 535.03 | 494.37 | 351.32 | Upgrade
|
| Revenue Growth (YoY) | 8.33% | -5.30% | 0.53% | 8.23% | 40.72% | 41.62% | Upgrade
|
| Cost of Revenue | 132.19 | 127.54 | 114.26 | 114.24 | 106.09 | 88.28 | Upgrade
|
| Gross Profit | 417.77 | 381.8 | 423.58 | 420.79 | 388.27 | 263.04 | Upgrade
|
| Selling, General & Admin | 381.98 | 386.97 | 306.41 | 263.18 | 225.45 | 184.62 | Upgrade
|
| Research & Development | 212.14 | 220.99 | 206.09 | 201.3 | 132.01 | 79 | Upgrade
|
| Operating Expenses | 594.11 | 607.96 | 512.5 | 464.49 | 357.46 | 263.63 | Upgrade
|
| Operating Income | -176.34 | -226.16 | -88.91 | -43.69 | 30.81 | -0.59 | Upgrade
|
| Interest Expense | -5.42 | -3.32 | -3.33 | -3.44 | -17.58 | -13.87 | Upgrade
|
| Interest & Investment Income | 23.4 | 19.64 | 10.96 | 0.79 | 1.79 | 4.4 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.8 | -0.8 | -3.52 | -4.03 | 2.65 | -0.43 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.79 | -0.79 | -1.26 | -1.37 | -0.47 | -0.34 | Upgrade
|
| EBT Excluding Unusual Items | -159.95 | -211.42 | -86.06 | -51.74 | 17.2 | -10.83 | Upgrade
|
| Merger & Restructuring Charges | -8.23 | -6.23 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 26.4 | 26.4 | 4.83 | 0.31 | 1.32 | 2.33 | Upgrade
|
| Asset Writedown | -0.48 | -0.48 | -0.61 | -0.64 | -0.41 | -0.33 | Upgrade
|
| Other Unusual Items | 1.14 | - | - | - | - | - | Upgrade
|
| Pretax Income | -141.13 | -191.74 | -81.85 | -52.08 | 18.1 | -8.82 | Upgrade
|
| Income Tax Expense | 27.57 | 15.3 | 10.69 | 6.28 | -1.71 | -1.59 | Upgrade
|
| Net Income | -168.7 | -207.04 | -92.53 | -58.35 | 19.81 | -7.23 | Upgrade
|
| Net Income to Common | -168.7 | -207.04 | -92.53 | -58.35 | 19.81 | -7.23 | Upgrade
|
| Shares Outstanding (Basic) | 107 | 106 | 105 | 103 | 101 | 97 | Upgrade
|
| Shares Outstanding (Diluted) | 107 | 106 | 105 | 103 | 109 | 97 | Upgrade
|
| Shares Change (YoY) | 1.61% | 1.65% | 1.19% | -5.00% | 11.97% | 5.89% | Upgrade
|
| EPS (Basic) | -1.57 | -1.95 | -0.88 | -0.56 | 0.20 | -0.07 | Upgrade
|
| EPS (Diluted) | -1.58 | -1.95 | -0.88 | -0.56 | 0.18 | -0.07 | Upgrade
|
| Free Cash Flow | -104.47 | -100.43 | 9.43 | 58.59 | 84.18 | 16.14 | Upgrade
|
| Free Cash Flow Per Share | -0.98 | -0.94 | 0.09 | 0.57 | 0.77 | 0.17 | Upgrade
|
| Gross Margin | 75.96% | 74.96% | 78.76% | 78.65% | 78.54% | 74.87% | Upgrade
|
| Operating Margin | -32.06% | -44.40% | -16.53% | -8.17% | 6.23% | -0.17% | Upgrade
|
| Profit Margin | -30.67% | -40.65% | -17.20% | -10.91% | 4.01% | -2.06% | Upgrade
|
| Free Cash Flow Margin | -19.00% | -19.72% | 1.75% | 10.95% | 17.03% | 4.59% | Upgrade
|
| EBITDA | -166.42 | -216.46 | -79.34 | -34.53 | 38.56 | 6.19 | Upgrade
|
| EBITDA Margin | -30.26% | -42.50% | -14.75% | -6.45% | 7.80% | 1.76% | Upgrade
|
| D&A For EBITDA | 9.93 | 9.7 | 9.57 | 9.17 | 7.75 | 6.78 | Upgrade
|
| EBIT | -176.34 | -226.16 | -88.91 | -43.69 | 30.81 | -0.59 | Upgrade
|
| EBIT Margin | -32.06% | -44.40% | -16.53% | -8.17% | 6.23% | -0.17% | Upgrade
|
Source: S&P Capital IQ. Standard template.